3GIULIARI G P, SADAKA A, CHANG P Y, et al. Diabetic papil- lopathy: current and new treatment options [ J ]. Curr Diabetes Re,, 2011, 7(3) : 171 -175.
4VARMA R, MACIAS G L, TORRES M, et al. Biologic risk fac- tors associated with diabetic retinopathy: the Los Angeles Latino Eye Study[ J]. Ophthalmology, 2007, 114(7) : 1332 - 1340.
6KASTHURI R S, GLOVER S L, BOLES J, et al. Tissue factor and issue factor pathway inhibitor as key regulators of global he- mostasis: measurement of their levels in coagulation assays [ J ]. Semin Thromb Hemost, 2010, 36(7): 764 -771.
7PARK K, CHEN Y, HU Y, et al. Nanoparticle -mediated ex- pression of an angiogenic inhibitor ameliorates ischemia - induced retinal neovasculatization and diabetes - induced retinal vascular leakage[J]. Diabetes, 2009, 58(8): 1902- 1913.
8BUTENAS S, BOUCHARD B A, BMMMEL ZIEDINS K E, et al. Tissue factor activity in whole blood[J]. Blood, 2005, 105(7) : 2764 - 2770.
9BRUMMEL ZIEDINS K, UNDAS A, ORFEO T, et al. Thrombio generation in acute coronary syndrome and stable coronary artery disease : Dependence on plasma factor composition [ J ]- J Thromb Haemost, 2008, 6(1 ) : 104 - 110.
10BECKER R C, MAHAFFEY K W, YANG H, et al. Heparin. as- socimed anti - Xa activity and platelet--derived and proin - flam- matoiy biomarkers in moderate to high - risk patients with acute coronary syndrume[ J ] J Thromb Thrombulysis, 2011, 31 ( 2 ) : 146 - 153.
